Dyne Therapeutics, Inc. (DYN) announced on Tuesday that Doug Kerr will take on the role of chief medical officer, replacing Wildon Farwell.
Susanna High, chief operating officer, and Jonathan McNeill, chief business officer, are stepping down to explore new opportunities.
To support ongoing clinical initiatives Farwell will continue with the company full-time, until the end of 2024.
Kerr has over 25 years of experience in clinical development, especially in neurology. Before joining Dyne, he was a venture partner at Atlas Venture and was CMO at Generation Bio.
Additionally, Johanna Friedl-Naderer, former executive VP and COO at Vir Biotechnology will assume the position of chief commercial officer, while Lucia Celona has been named chief human resources officer.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.